Topical NMN for Hair Regrowth - Quick Reference Sheet

Topical NMN for Hair Regrowth

Created on 09/26/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Grok 4 – Audit

Topical nicotinamide mononucleotide is a vitamin B3-related molecule applied to skin in the hope of restarting thinning scalp hair. The interest is longevity: follicles are busy tissue, and the energy-transfer molecule this preparation feeds declines with age. The regrowth signal is from mouse skin after hair removal and human follicle cells in a dish, not trials in people. A breakdown product slowed human follicles kept outside the body. (Full Review)

Protocol

No consensus human regimen
None identified
Published human hair trials of this route were not found
Preclinical skin concentration
0.5% NMN daily
Mouse skin after hair removal; not a transferred human dose
Single versus split application
Once daily
Not studied on a scalp; the mouse regimen was a single daily skin application, not divided doses
Time to effect
Short hair
Within about 10 days
Mice, after hair removal
Skin darkening
Within days
Mice, after hair removal
Human topical time course
None exists
Animal speed is not a forecast for scalp coverage

Benefits

Contraindications
  • Pregnancy
  • Lactation
Key Interactions
  • Topical minoxidil
  • 5-alpha-reductase inhibitors (finasteride, dutasteride; drugs that lower DHT)
  • Oral NAD+ precursors (nicotinamide riboside, nicotinamide)
  • Drugs and supplements that stress methylation (spending methyl groups; methotrexate, high-dose niacin) (mainly for oral use)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Slower follicle growth if the molecule breaks down
  • Speculative: Inflammatory output of old cells
  • Speculative: No studied exposure in pregnancy or lactation

Monitoring

Marker Target Why
Terminal hair density (thick scalp hairs) No established target; track change from the person's own baseline Shows whether more thick scalp hairs are present
Hair-shaft diameter No established target; track microns against the person's own baseline Thinning shafts mark miniaturization (shafts shrinking)
Ferritin 50–100 ng/mL Low iron stores cause shedding unrelated to the topical
TSH 0.5–2.5 mIU/L Thyroid excess or deficiency changes the hair cycle
25-hydroxyvitamin D 40–60 ng/mL Deficiency is a reversible contributor to shedding

Cadence: Baseline photographs and a same-site hair count before any reading of a topical preparation. Photographs and, where available, a phototrichogram (magnified hair count) at 12 weeks and then every 6 months. Labs repeat only if the baseline value was outside the range being tracked.

Qualitative Assessment

  • Shedding on wash or brush days, counted the same way each time
  • Scalp comfort: itch, redness, or flaking after application
  • Coverage on repeat photographs of the same part and hairline
  • Whether any change survives a planned break, which the discontinuation literature does not yet define